Next Article in Journal
Homotopy Phases of FQHE with Long-Range Quantum Entanglement in Monolayer and Bilayer Hall Systems
Next Article in Special Issue
Surface Modification of Iron Oxide-Based Magnetic Nanoparticles for Cerebral Theranostics: Application and Prospection
Previous Article in Journal
Effect-Based Approach to Assess Nanostructured Cellulose Sponge Removal Efficacy of Zinc Ions from Seawater to Prevent Ecological Risks
Previous Article in Special Issue
Engineering Core-Shell Structures of Magnetic Ferrite Nanoparticles for High Hyperthermia Performance
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Nanomaterials
Volume 10
Issue 7
10.3390/nano10071284
nanomaterials-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Capturing Amyloid-β Oligomers by Stirring with Microscaled Iron Oxide Stir Bars into Magnetic Plaques to Reduce Cytotoxicity toward Neuronal Cells

by
Yuan-Chung Tsai
1,
Jing-Chian Luo
1,
Te-I Liu
1,
I-Lin Lu
1,2,
Ming-Yin Shen
1,3,
Chun-Yu Chuang
1,
Chorng-Shyan Chern
4 and
Hsin-Cheng Chiu
1,*
1
Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu 30013, Taiwan
2
Department of Surgery, Hsinchu Mackay Memorial Hospital, Hsinchu 30071, Taiwan
3
Department of Surgery, China Medical University Hospital-Hsinchu Branch, Hsinchu 30059, Taiwan
4
Department of Chemical Engineering, National Taiwan University of Science and Technology, Taipei 10607, Taiwan
*
Author to whom correspondence should be addressed.
Nanomaterials 2020, 10(7), 1284; https://doi.org/10.3390/nano10071284
Submission received: 29 April 2020 / Revised: 24 June 2020 / Accepted: 28 June 2020 / Published: 30 June 2020
(This article belongs to the Special Issue Magnetic Nanoparticle-Based Hyperthermia and Theranostics)
Browse Figures
Versions Notes

Abstract

Soluble amyloid-β oligomers (oAβ42)-induced neuronal death and inflammation response has been recognized as one of the major causes of Alzheimer’s disease (AD). In this work, a novel strategy adopting silica-coated iron oxide stir bar (MSB)-based AD therapy system via magnetic stirring-induced capture of oAβ42 into magnetic plaques (mpAβ42) and activation of microglia on cellular plaque clearance was developed. With oAβ42 being effectively converted into mpAβ42, the neurotoxicity toward neuronal cells was thus greatly reduced. In addition to the good preservation of neurite outgrowth through the diminished uptake of oAβ42, neurons treated with oAβ42 under magnetic stirring also exhibited comparable neuron-specific protein expression to those in the absence of oAβ42. The phagocytic uptake of mpAβ42 by microglia was enhanced significantly as compared to the counterpart of oAβ42, and the M1 polarization of microglia often occurring after the uptake of oAβ42 restricted to an appreciable extent. As a result, the inflammation induced by pro-inflammatory cytokines was greatly alleviated.

Graphical Abstract

1. Introduction

The abnormal accumulation of amyloid-β oligomers (oAβ42) and protofibrils within neuronal/microglial cells is believed to be crucial to Alzheimer’s disease (AD) progression [1]. Although new strategies in therapeutic regimens including β-secreatase 1 (BACE1) inhibition, γ-secretase suppression, and passive anti-amyloid-β immunotherapies [2,3] have been proposed, the efficacy is still not significant probably due to the incomplete elimination of oAβ42 species in brain. For instance, an oral BACE1 inhibitor, Lanabecestat, was discontinued in phase III clinical study owing to its insignificant therapeutic efficacy [4]. A passive anti-amyloid-β antibody drug, solanezumab, was failed in clinical trial due to the poor improvement on cognitive impairment [5]. In addition to the neurotoxicity of oAβ42 from the impairment of synaptic plasticity in association with the interaction of oAβ42 with cellular prion protein [6,7], oAβ42 may further induce microglial cell polarization into M1 phenotype along with severe phagocytic function attenuation toward toxic species [8,9]. Moreover, the neuroinflammation induced by pro-inflammatory cytokines released from M1 type microglial cells further enhances the apoptosis of neuronal cells [10,11,12]. By contrast, the M2 phenotype microglial cells exhibit a superior phagocytic capability to eliminate Aβ42 in comparison with other resident central nervous system (CNS) immune cells such as M1 type microglial cells, astrocytes, and possibly neuronal cells [13,14,15]. Furthermore, the secretion of neurotrophic factors and anti-inflammatory cytokines from M2 microglial cells in brain regions helps repair CNS damage and alleviate inflammation [16]. Unfortunately, naive microglial cells localized in neuroinflammatory regions are apt to differentiate into the M1 phenotype, which further deteriorates inflammatory conditions [17,18].
It has been reported that sulindac sulfide and orcein-related drug (O) can be employed as stimulators for accelerating the aggregation of oAβ42, which reduce its neurotoxicity for effective AD treatment [19,20]. On the other hand, β-secretase 1 (BACE) inhibitor was found capable of reducing soluble form of Aβ42 (oAβ42) accompanied by rescue of cognitive dysfunction and memory deficits in a mouse model of AD [21]. Similarly, Meier et al. employed a BACE inhibitor (NB-360) to serve as a scavenger for Aβ reduction in tg-ArcSwe mice [22]. Nevertheless, these approaches are somewhat limited due to the ineffective elimination of oAβ42.
This work was aimed to develop a novel therapeutic strategy to achieve rapid capture and subsequent removal of oAβ42 and prevention of neuroinflammation for potential AD treatment. Distinct from small molecule drugs as aforementioned that require a slow progression process involved in the oAβ42 aggregation, a MSB-based approach was developed and characterized in relation with the capability to effectively capture oAβ42 into mpAβ42 by facile magnetic stirring. The MSBs comprising aligned superparamagnetic iron oxide nanoparticles (SPIONs) coated by silica in rod shape were prepared and characterized with respect to the morphology by scanning electron microscopic (SEM) examination and the stirring effect under rotating magnetic field. The therapeutic effect on neuron cells by rapid capture of oAβ42 with the aid of MSBs under magnetic stirring into mpAβ42 in terms of cell viability and morphology, neuron-specific protein expression, and oAβ42-induced neuron membrane damage was extensively examined. A reduction in the uptake of oAβ42 by microglial cells also leads to a significant decrease in polarization of microglial cells into the M1 type. This will then greatly reduce the level of the pro-inflammatory cytokines. The internalization efficiency of oAβ42 and mpAβ42 by microglial cells and the effect on cell polarization was thus investigated. The in vivo biocompatibility of the MSB-based therapeutic system with stirring in terms of brain tissue damage from C57BL/6 mice was examined by the immunohistochemistry (IHC) staining. To the best of our knowledge, this is the first study demonstrating the rapid capture of oAβ42 by MSB under magnetic stirring and its potential for AD treatment. The therapeutic strategy developed herein is illustrated schematically in Figure 1.

2. Materials and Methods

2.1. Reagents and Materials

Preparation of oleic acid coated SPIONs (OA-SPIONs) was conducted as reported previously [23]. Congo red (CR), thioflavin T (ThT), and hematoxylin and eosin (H&E) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Tetraethyl orthosilicate (TEOS) and 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) were acquired from Alfa Aesar (Haverhill, MA, USA). Aβ42 peptide (DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA) was acquired from Chinapeptide (Shanghai, China). Lactate dehydrogenase (LDH) assay kit, Hoechst 33342, rabbit anti-oligomer (A11) polyclonal antibody (AHB0052) and goat anti-mouse IgG secondary antibody (Alexa Fluor 568) were purchased from Thermo Fisher Scientific (Waltham, MA, USA). Anti-mouse F-actin antibody, goat anti-mouse IgG secondary antibody (Alexa Fluor 488), and donkey anti-rabbit IgG secondary antibody (Alexa Fluor 594) were obtained from Abcam (Cambridge, UK). Microtubule-associated protein 2 (MAP2) antibody and anti-human β-amyloid (6E10) antibody were purchased from BioLegend (San Diego, CA, USA). Neuronal nuclei (NeuN) antibody and neurofilament M (NF-M) antibody were supplied by Merck (Darmstadt, Germany). 4’,6-Diamidino-2-phenylindole (DAPI), singlet oxygen sensor green (SOSG) reagent and anti-mouse caspase-3 antibody were purchased by Invitrogen (Eugene, OR, USA). N2a (murine neuroblastoma cells) and BV-2 (murine microglial cells) were obtained from Food Industry Research and Development Institute (Hsinchu City, Taiwan). C57BL/6J male mice were purchased from the National Laboratory Animal Center, Taiwan. Approved guidelines for the care and use of laboratory animals by the Institutional Animal Care and Use Committee (IACUC: 10129) were followed.

2.2. Preparation and Characterization of MSBs

The lauric acid/oleic acid coated SPIONs (LA/OA-SPIONs) were prepared using the oil-in-water emulsion technique. LA sodium salt (200 mg in 15 mL deionized water) and OA-SPIONs (15 mg in 200 μL chloroform) were mixed by ultrasonication for 10 min in an ice–water bath. This was followed by removal of chloroform by rotary evaporation. The resultant LA/OA-SPIONs were well dispersed in deionized water and phosphate buffered saline (PBS). The mean hydrodynamic diameters (Dh), size distributions (polydispersity index, PDI), and zeta potentials of OA- and LA/OA-SPIONs in n-hexane and PBS, respectively, were determined by dynamic light scattering (DLS, ZetaSizer Nano Series, Malvern, UK). Preparation of MSBs was carried out according to the method previously reported [24]. The MSBs in microscale were prepared according to the method reported previously by neodymium magnet assisted alignment of SPIONs into rod-shaped structure in aqueous phase while the SPION surfaces were concomitantly coated with TEOS-based silica to maintain the desired particle morphology and improve the colloidal stability. In brief, LA/OA-SPIONs (0.05 mg) were dispersed in a mixture of isopropanol (1 mL) and deionized water (600 μL) under sonication. A NH4OH solution (28%, 20 μL) and TEOS (20 μL) was added in sequence into the aqueous suspension of LA/OA-SPIONs and the reaction solution was then placed between two 10 × 20 × 30 mm neodymium magnets (4,100 gauss) at a distance of 1.0 cm for 20 min at room temperature. After removal from the magnetic field, the sample was purified through centrifugation (1,900 g, 2 min) with deionized water three times and re-dispersed in deionized water. The morphology of SPIONs and MSBs was examined by transmission electron microscope (TEM) (T7700, Hitachi, Tokyo, Japan). SEM examination was conducted on a Hitachi S-4700 field emission microscope. Characterization of superparamagnetic properties was carried out on a superconducting quantum interference device (SQUID) magnetometer at 300 K (MPMS-XL Quantum Design, San Diego, CA, USA). The Fe content of OA-SPIONs was determined by thermogravimetric analyzer (TGA, Mettler-Toledo, Greifensee, Switzerland) at a heating rate of 10 °C min−1. X-ray diffraction (XRD) measurements of OA-SPIONs and LA/OA-SPIONs were conducted on a TTRax III diffractometer (Rigaku, Japan).

2.3. Preparation and Characterization of oAβ42 and Natural Aβ42 Plaques (npAβ42)

oAβ42 and npAβ42 were prepared and characterized according to the methods described previously [25,26,27,28]. The Aβ42 peptide was initially dissolved in HFIP (1.0 mM) and the solution was divided into aliquotes in sterile microcentrifuge tubes. HFIP was then removed under vacuum. The peptide film thus obtained was stored in dessicator at −20 °C before use. The β-sheet motif of npAβ42 was examined by ThT assay and CR spectroscopic analysis. For ThT assay, Aβ42 in dimethyl sulphoxide (DMSO) was added with 100 μL PBS (pH 7.4, ionic strength 0.15 M) to a concentration of 20 μM in 96-well plates. ThT was added (10 μM) and the solution was incubated at 37 °C as a function of time. The fluorescence intensity of ThT was determined by a microplate reader (Infinite M200 PRO, Männedorf, Switzerland). The excitation was performed at 442 nm and the emission spectrum was recorded in the range of 445–482 nm. The characteristic absorbance of CR at 490 nm and the red shift in the CR absorption band with the occurrence of npAβ42 in the range of 490–540 nm was determined using a UV–vis spectrophotometer. For the 100 μM oAβ42 preparation, the Aβ42 peptide film was first dissolved in dry DMSO to a concentration of 5 mM. The solution was then diluted with the Dulbecco’s Modified Eagle’s Medium (DMEM) (phenol red-free) to an Aβ42 concentration of 100 μM. The solution was further incubated at 4 °C for 24 h. The morphology of oAβ42 and npAβ42 was examined by transmission electron microscopy (TEM, HT7700, Hitachi, Tokyo, Japan). Briefly, the Aβ dispersion was dropped onto a carbon-coated copper grid (200 mesh copper grids, Ted Pella, Inc., Redding, CA, USA) and stained with 1 wt % uranyl acetate solution for 1 min and dried at 25 °C for 2 days before measurements. The stained samples were analyzed by TEM operating at an accelerating voltage of 100 kV.

2.4. In Vitro Stirring-Induced oAβ42 Capture

The capture effect of the magnetic stirring treatment with MSBs on oAβ42 species of varying concentrations (0.3–160 μM) under rotating magnetic field at 2500 rpm was determined by fluorescence microscope (Olympus IX70, Tokyo, Japan). Rotating magnetic stirring was conducted on an IKA magnetic stirrer (color squid, Staufen, Germany) with a dynamic magnetic attraction force in the range 15–30 mT. The stirring speed was calibrated with an external speed sensor, which reacts to magnetic impulses. The power consumption is 3 W and the motor rating output is 2 W. For the preparation of 20 μM oAβ42, the peptide film prepared previously was dissolved in dry DMSO to a concentration of 5 mM. The solution was then diluted with the DMEM medium (phenol red-free) to an Aβ42 concentration of 20 μM, followed by re-incubation at 4 °C for 24 h. The oAβ42 (20 μM) was first treated with magnetic stirring as a function of the concentration of MSBs at 2500 rpm for 20 min. The Aβ42 was then stained with 10 μM ThT (λex = 442 nm, λem = 445–482 nm) and CR (λex = 497 nm, λem = 596–632 nm) dyes. The total and mean areas of the stained mpAβ42 were quantified with the functions of Image-Pro Plus 6.0 (n = 10). The morphology of mpAβ42 was examined by TEM, scanning probe microscopy (SPM, tapping mode, Bruker, Model-Dimension Icon, Camarillo, CA, USA) and atomic force microscope (AFM, Bruker, Santa Barbara, CA, USA) [29,30,31,32].

2.5. Cell Membrane Damage and Neurite Outgrowth Impairment

3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and trypan blue assays were used to determine the cell viability of N2a cells co-incubated with oAβ42 species (160 μM) under the MSB stirring treatment (2500 rpm, 2 h). For 160 μM oAβ42 preparation, the peptide film obtained previously was dissolved in dry DMSO to a concentration of 5 mM. The solution was then diluted with the DMEM medium (phenol red-free) to an Aβ42 concentration of 160 μM, followed by re-incubation at 4 °C for 24 h. N2a cells were first seeded into 96-well plates at a concentration of 5 × 103 cells/well in 200 μL DMEM, containing 10% fetal bovine serum (FBS) and 1% penicillin, and incubated at 37 °C overnight in an atmosphere of 5% CO2. N2a cells were then co-incubated with oAβ42 (160 μM) with or without MSB-based (144 μg mL−1) stirring at 2500 rpm for another 2 h. After being washed twice with PBS, cells were re-incubated in DMEM for another 24 h. MTT (0.25 μg/mL) in DMEM (200 μL) was added into each well, followed by re-incubation at 37 °C for 4 h. The culture medium was then replaced with DMSO (100 μL) and the absorbance of each well at 570 nm was determined by the microplate reader. The MTT assay for the cell viability evaluation was performed based upon the measurement of the cellular metabolic activity, in particular with respect to the activity of mitochondria reductase (dehydrogenase) by colorimetric determination. Trypan blue assay was used to determine the number of viable N2a cells. In brief, trypan blue solution (0.4%) in DMEM (200 μL) was co-incubated with N2a cells being treated with either oAβ42 (160 μM) alone or oAβ42/magnetic stirring (2500 rpm, 2 h) for 24 h at 37 °C. The viable N2a cells with intact cell membranes that prevent trypan blue from permeation into cells was then examined by optical microscopy. The effects of oAβ42 and mpAβ42 on neuron apoptosis in terms of the level of cell membrane damage was evaluated by measuring the release of LDH, a cytosolic enzyme from the damage cells [33]. The neurite outgrowth was examined by laser scanning confocal microscope (LSCM, ZEISS LSM-780, Jena, Germany). The cell nuclei and cytoskeletons were stained with Hoechst 33342 and CytoPainter F-actin Staining Kit-Green Fluorescence, respectively. Mean number and length (μm) of neurites were calculated by Neurolucida software (Version 8, MBF Bioscience, USA), respectively. The mean neurite length was defined herein as the ratio of the sum of neurite length to the number of neurite. At least three independent experiments were performed in this study, and at least 50 cells quantified per experiment.

2.6. Cell Functions

The cellular functions in terms of specific protein expression were examined by western blotting. Proteins were subjected to a 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidene difluoride (PVDF) membrane. The PVDF membrane was blocked using 5% nonfat milk blocking buffer with anti-MAP-2, NF-M, and NeuN primary antibody at 4 °C for 24 h. It was then incubated at 37 °C for 1 h with horseradish peroxidase-conjugated secondary antibody. β-Actin was used as the loading control. The area and signal intensity of the detected bands were determined using the Molecular Imager PharosFX Plus System and quantified using the ImageJ software (v1.33, National Institute of Mental Health, MD, USA). For the LSCM examination, N2a cells on glass coverslips were treated with MSBs (144 μg), free oAβ42 (160 μM), and oAβ42/MSBs, respectively, either with or without 2 h magnetic stirring (2500 rpm) at 37 °C. With additional 22 h incubation, the cells were washed with PBS three times and fixed with 4% formaldehyde. Triton X-100 (0.1%) was added to increase the cell permeability. After being rinsed with PBS, the cells were then co-incubated in sequence with mouse anti-mouse MAP-2 antibody as the primary antibody and goat anti-mouse Alexa Fluor 488 as the secondary antibody at ambient temperature. Cells were further IHC stained for NF-M similarly while the rabbit anti mouse NF-M and donkey anti-rabbit antibodies (conjugated with Alexa Fluor 594) as primary and secondary antibody was employed for NF-M detection. Finally, cells were stained with Hoechst 33342 (5 μg mL−1) to identify cell nuclei.

2.7. Phagocytic Activity of Microglial Cells

BV-2 cells were adopted as a microglia cell model for evaluating the uptake of Aβ42 in different forms (i.e., oAβ42, npAβ42 and mpAβ42). BV-2 cells (3 × 105 cells per well) were seeded on glass coverslips and cultured at 37 °C under 5% CO2/air overnight. This was followed by co-incubation with the Aβ42 species at varying concentrations. With 6 h co-incubation, the coverslips were washed with PBS twice, fixed with 4% paraformaldehyde and stained with 6E10 for 10 min in sequence. The extent of cellular uptake of Aβ42 in different forms by microglia was visualized at the excitation and emission wavelengths of 488 nm and 590 nm, respectively, with LSCM.

2.8. Cytokine Production

Levels of IL-1β, TNF-α and IL-10 released from BV-2 cells after uptake of Aβ42 species of various structures were examined by enzyme-linked immunosorbent assay (ELISA). A 96-well tailor-made mouse multi-analyte ELISArray kit (Qiagen, SA Biosciences, Hilden, UK) was employed to determine the concentrations of TNF-α, IL-1β, and IL-10 in the collected culture media according to the manufacturer’s instruction.

2.9. Brain Tissue Toxicity and Damage with MSB Stirring

The intracranial injection of 2 μL of the aqueous MSB dispersion (0.5 and 1.0 μg in 2 mL of F-12K medium, respectively) into the hippocampus area of healthy C57BL/6J mice with the magnetic stirring was conducted in this work to evaluate the in vivo brain tissue toxicity and damage by MSB stirring [34,35,36]. In brief, male C57BL/6J mice (6–8 weeks old) were first anesthetized with Zoletil-Rompun by intraperitoneal injection and placed in an animal stereotaxic apparatus (Stoelting, Wood Dale, IL, USA). Two μL of the aqueous MSB dispersion were injected intracranially into the hippocampus area using a 10 μL Hamilton syringe equipped on the stereotaxic instrument with a 27-gauge needle and a microinjection auto-pump (KD Scientific, Hollison, MA, USA). After the needle was gently withdrawn, the burr hole was immediately sealed with bone wax and the surgical incision was sutured. This was followed by magnetic stirring (2400 rpm) over 20 min. At the prescribed time points, the brains were isolated and sectioned. The reactive oxygen species (ROS) level induced from Fe2+ and Fe3+ ions (Fenton reaction) with the dissolution of MSBs was determined by SOSG. The cell apoptosis in brain tissue sections was examined by caspase 3 IHC staining. The Prussian blue staining was used to determine the Fe content in brain tissue with time. The hippocampus tissue sections were H&E stained for histologic examination under optical microscopy.

2.10. Statistical Analysis

All experiments were performed at least in triplicate and data were reported as mean ± standard deviation. Statistical significance was determined using one-way ANOVA and Bonferroni post-hoc test. Significant differences were defined as (*) p < 0.05, (**) p < 0.01, and (***) p < 0.005. Not significant differences were displayed as N.S. (p > 0.05).

3. Results and Discussion

3.1. Preparation and Characterization of MSBs

The MSBs in microscale were prepared according to the method reported previously [24]. Through the neodymium magnet assisted alignment of SPIONs into rod-shaped structure in aqueous phase, the SPION surfaces were concomitantly coated with TEOS-based silica to maintain the desired particle morphology and improve the colloidal stability. The particle surface of SPIONs in the form of OA-SPIONs prepared by the thermal decomposition technique were modified with LA by hydrophobic association to improve the aqueous colloidal dispersion. The results obtained from characterization of OA-SPIONs and LA/OA-SPIONs by TEM, TGA, SQUID, and XRD are shown in Figure S1. TEM images of LA/OA-SPIONs and OA-SPIONs confirm their spherical particle morphology. The resultant LA/OA-SPIONs still retain excellent superparamagnetic behavior with similar hysteresis to OA-SPIONs (Figure S1d). In addition, the XRD patterns of OA-SPIONs and LA/OA-SPIONs show high crystallinity in the spherical phase structure of Fe3O4 (JCPDS: 65-3107) (Figure S1e). Table S1 also shows the mean hydrodynamic diameters of OA-SPIONs in n-hexane and LA/OA-SPIONs in PBS and the zeta potential of LA/OA-SPIONs at pH 7.4. The optical microscopic, SEM, TEM, and high resolution TEM (HR-TEM) images of the MSBs developed herein are shown in Figure 2. The dimensions of MSBs were ca. 2.9 ± 0.7 μm in length and 132.4 ± 4.1 nm in diameter with the thickness of silica coating at ca. 45.5 ± 5.2 nm estimated by TEM image. The HR-TEM image further confirms the confinement of LA/OA-SPIONs in a relatively linear architecture within the silica coat (Figure 2d).
In the absence of magnetic field, MSBs remained as rod-like particles randomly dispersed in the continuous aqueous phase, as illustrated in Figure S2a. By contrast, MSBs became uniformly aligned in response to the direction of the applied external magnetic field (Figure S2b). The stirring effect of MSBs was observed by the accelerated dispersion of rhodamine B employed as a fluorescence dye in a water droplet in the presence of MSBs under an external magnetic rotating field (Figure S2c). Without magnetic stirring, the dye species resided locally within the water droplet. On the contrary, the dye species subjected to magnetic stirring became rapidly dispersed in the droplet and the extent of dispersion was dependent on the stirring speed and duration. Notably, a homogenous aqueous solution of rhodamine B was achieved over 20 s of stirring at 2500 rpm. The rapid rotation of MSBs is illustrated in Video S1, in which individual rotations of MSBs at various stirring speeds were recorded. The blinking phenomenon caused by light scattering during magnetic stirring was also observed (Video S2), similar to what has been reported elsewhere [37]. The colloidal stability of MSBs in different aqueous milieus was also evaluated in terms of the time-evolved change of light scattering intensity by DLS measurements. Figure S3 illustrates negligible variations in count rate of the aqueous MSB dispersions over a period of 1 h, indicating excellent colloidal stability under 500; 1500; or 2500 rpm magnetic stirring. Similar observation from the silica-coated nanoparticles was reported in the literature [38]. Being quite similar in surface modification, silica coating exhibited a strong resistance against both salt-induced aggregation in PBS and protein adsorption-evolved coagulation in Dulbecco’s modified Eagle medium (DMEM) solution primarily because of the high negative surface charge density of MSBs (ζ-potential of ca. −35 mV).

3.2. Capture Efficiency of Aβ42 by Magnetic Stirring of MSBs and In Vitro Therapeutic Efficacy

Rapid agglutination and capture of oAβ42 into mpAβ42 in cell culture medium by means of magnetic stirring with MSBs was studied first by fluorescence microscopy. As shown by the fluorescence images in Figure 3, the signal areas of both ThT and CR in the aqueous oAβ42 solution subjected to magnetic stirring treatment increase dramatically compared to those without magnetic stirring treatment. These signals were observed obviously owing to the formation of oAβ42 aggregates. The total areas detected are in the range 2 × 105~3 × 105 μm2 while the mean areas in the range 110–130 μm2 with oAβ42 being treated with magnetic stirring (Figure 3). The signal areas from ThT and CR overlapped mostly, indicating that both staining occurred at the same places. At constant stirring speed (2500 rpm), a rather weak dependence of the total signal area of the ThT/CR stained Aβ42 aggregates on the concentration of MSB in the range 144–576 μg/mL employed herein was observed. The effect of the MSB concentration (144–576 μg/mL) on the mean signal area (i.e., the oAβ42 aggregate size) is also essentially insignificant. In contrast to the magnetic stirring effect, the fluorescence signals of both ThT and CR were barely detected from the aqueous solution of oAβ42 without stirring over a period of 20 min. This result strongly suggests that the oAβ42 aggregate formation is substantially promoted by the magnetic stirring provided by MSBs as compared to the counterpart that is not subjected to stirring. It is noteworthy that the sound capture of oAβ42 is successfully achieved by magnetic stirring even at a concentration of 0.3 μM. This implies the potential of the magnetic stirring with MSBs in practical applications for AD treatment (Figure S4).
The capture of oAβ42 into mpAβ42 via magnetic stirring with MSBs was further supported by comparison of the oAβ42 images before and after the magnetic stirring treatment using the TEM and AFM techniques (Figure 4). The TEM images clearly demonstrate the agglutination of oAβ42 after the magnetic stirring with MSBs while the small oAβ42 species were well separated from MSBs in the absence of the magnetic stirring treatment (Figure 4a). Both the 2-D and 3-D AFM topographic maps also corroborate the oAβ42 plaque formation promoted by MSB stirring with the plaque size being enormously enlarged in comparison with the oligomers (Figure 4b).
Figure S5a shows that the fluorescence intensity of ThT in the aqueous oAβ42 solution increases significantly as the time-evolved npAβ42 form although over a relatively prolonged period of time (5–7 days) is required. The increase of the fluorescence intensity is ascribed to the restriction of the rotation of both benzylamine and benzathiole rings of ThT once the dye binds with Aβ42 in the forms of both fibrils and naturally occurring plaques which are enriched with the β-sheet structure [39,40,41,42]. Similar to the data reported elsewhere [43,44], a red shift in the wavelength of the maximum absorbance of CR from 490 to 540 nm was observed upon the association of CR with the insoluble β-sheet rich Aβ42 aggregates such as fibrils and npAβ42 (Figure S5b). Figure S5c,d show the TEM images of oAβ42 and npAβ42, respectively. The latter was obtained from the incubation of oAβ42 in PBS at 37 °C under mild shaking over 7 days. TEM images show that npAβ42 fully comprises fibrils while the aggregate size (ca. 70 μm2 attained from the fluorescence microscopic examination) is somewhat smaller than that of mpAβ42 (ca. 125 μm2). It is interesting to note that the ThT fluorescence intensity reaches a plateau value of ca. 35,000 (a.u.) for the npAβ42 formation compared to ca. 20,000 for ThT with mpAβ42 at the same concentration of Aβ42 (20 μM) and ca. 1000 for ThT alone in aqueous solution. Comparing the structures of npAβ42 and oAβ42 shown by TEM images, obviously oAβ42 species are rather void of the fibril structure (Figure S5c), which by contrast predominates in npAβ42 (Figure S5d). With mpAβ42 being formed via the rapid capture of oAβ42 with the MSB stirring treatment, a decrease in the fluorescence intensity of ThT when bound with mpAβ42 in comparison with the signal intensity associated with the npAβ42 formation can thus be expected. Since the size of npAβ42 is smaller than that of mpAβ42, the effect of the magnetic stirring treatment on npAβ42 was also examined. Figure S6a shows the capability of the MSB stirring to readily capture npAβ42 (20 μM) into larger aggregates at a speed of 2500 rpm over 20 min. The extent of aggregation in terms of the detected total signal area closely correlating to the concentration of MSB employed for magnetic stirring was also observed (Figure S6b).
The effects of structural transformation from oAβ42 to mpAβ42 by magnetic stirring treatment on neuron cells (N2a) was investigated in terms of cell viability, cell morphology, and cell-specific protein expression. First, the in vitro cytotoxicity of mpAβ42 induced by the rapid capture of oAβ42 species against N2a cells was evaluated using MTT and trypan blue assays. In the absence of oAβ42, MSBs (144 μg mL−1) without or with magnetic stirring at 2500 rpm for 2 h resulted in negligible cell death as measured by MTT assay (Figure 5a). The cell viability was also barely affected by the stirring speed (0; 500; 1500; and 2500 rpm) and the concentration of MSB (up to 144 μg mL−1) employed for the rapid oAβ42 capture in the culture medium (Figure S7). By contrast, with those cells being exposed to oAβ42 without the stirring treatment, the cell viability was significantly reduced compared to the cell only control. This result is consistent with those reported previously that oAβ42 species are responsible in large measure for neuron toxicity in AD [45,46,47,48]. Nevertheless, an essentially full retention of the viability of N2a cells incubated with oAβ42 was observed when the N2a/oAβ42 suspension was concomitantly treated with the MSB stirring. The greatly reduced cytotoxicity is ascribed to the rapid capture of the oAβ42 into large aggregates by which the Aβ42 structure is appreciably altered and their entry into N2a cells extremely limited. The cytotoxicity of oAβ42 against N2a cells via the MSB stirring treatment was also evaluated by the trypan blue staining as a measure of cell apoptosis. As shown in Figure 5b, the cytotoxicity of oAβ42 was appreciably reduced as these toxic species were captured and converted into large magnetic aggregates. Figure 5c illustrates that the LDH release from N2a cells caused by oAβ42 is greatly reduced by the magnetic stirring treatment in comparison with the run without the treatment. Apparently, the cytotoxicity of oAβ42 species was considerably alleviated by their magnetic capture into large aggregates, thereby leading to the significant reduction of cellular uptake of oAβ42 by N2a cells for neurotoxicity attenuation. Figure 5d demonstrates the comparable neuron-specific protein expression of N2a cells in the presence of oAβ42 subjected to magnetic stirring to the positive control. In contrast, the neuron specific protein expression was significantly suppressed for the run without the capture of oAβ42 species into large aggregates of oAβ42/MSBs. Note that the proteins chosen for study include MAP2 and NF-M. Finally, further supporting evidence was provided by the neurite morphology. As shown in Figure S8, the morphology of N2a cells, in particular the neurites (axons and dendrites), was well preserved when they were treated by oAβ42 in virtue of the superior capture effect of magnetic stirring. The neurite length of N2a cells (ca. 20 μm) in the magnetic stirring-treated group was well retained as comparable to the positive control without oAβ42. By contrast, the length of neurites was reduced to ca. 3 μm with the cells being treated with oAβ42 only. All these results strongly suggest that the MSB stirring treatment is highly capable of capturing toxic oAβ42 species and, consequently, reducing their toxicity against neuronal cells. As a result, rather high cell integrity and viability are achieved.

3.3. Functionality of N2a Cells and Phagocytic Action of BV-2 Cells

The cellular functions in terms of specific protein expression after the rapid oAβ42 capture treatment on neuron cells were examined by western blotting. Figure 6 demonstrates that the MAP2 proteins, the NF-M protein, and NeuN were found normally expressed from N2a cells with a negligible effect of oAβ42 under magnetic stirring. On the other hand, the specific protein expression was significantly reduced in the negative control by oAβ42 without magnetic stirring. The quantification of the specific protein expression is also shown in Figure 6. Moreover, in the presence of npAβ42 instead of oAβ42, the specific expression of MAP2a, MAP2b, MAP2c, or NF-M on N2a cells was comparable to the blank control. This signifies that the neurotoxicity of both npAβ42 and mpAβ42 against N2a cells is substantially reduced compared to oAβ42 (Figure S9). In excellent agreement with the data obtained from the cell viability and morphology (Figure 5 and Figure S8), these results strongly imply that the effective therapeutic action is indeed achieved by capture of oAβ42 via MSBs under rotating magnetic field.
As illustrated in Figure 7 and Figure S10, BV-2 cells (as a microglial cell model) treated with oAβ42 species exhibited quite weak fluorescence signals from Triton X-100 facilitated intracellular IHC staining using 6E10 as the primary antibody. In contrast, the fluorescence signal intensity was greatly enhanced for the cells treated with either npAβ42 or mpAβ42. This is most likely due to the enhanced uptake of mpAβ42 (or npAβ42) aggregates with activating the toll-like receptor (TLR)-associated endocytosis [49,50,51,52]. It was reported that the interactions of TLR-4 with CD14 on cell membranes were enhanced through the activation of CD14 upon their binding with Aβ42 species, triggering the TLR/CD14-mediated endocytosis [53]. On the other hand, the enhanced uptake of mpAβ42 by BV-2 cells compared to npAβ42 (Figure 7) is presumably caused by their enlarged size that inevitably increases contacts with CD14 on the cell membrane, thereby facilitating the TLR-mediated phagocytosis. It has been recognized that the internalization of oAβ42 species by microglia induces the M1 phenotype polarization of the cells, known for the reduced phagocytic activity toward neurotoxic species [54]. This will then lead to an increase in neuron apoptosis.
As shown in Figure 8a,b, the production of the pro-inflammatory cytokines such as IL-1β and TNF-α from microglial cells after uptake of mpAβ42 (or npAβ42) was substantially reduced as compared to the uptake of oAβ42. This is also reflected by a significant increase in secretion of IL-10 (an anti-inflammatory cytokine) from microglial cells co-incubated with mpAβ42 (or npAβ42) aggregates as compared to oAβ42 species (Figure 8c). Comparing the differences in the levels of both pro-inflammatory cytokines and anti-inflammatory cytokines from microglia treated with oAβ42 species and plaques (mpAβ42 and npAβ42), respectively, the extent of the oAβ42-induced polarization of microglia to M1 type was reduced for the run with oAβ42 being captured and transformed into mpAβ42 (or npAβ42) via the magnetic stirring treatment. With the decreased pro-inflammatory cytokines and the increased anti-inflammatory cytokines, the neuroinflammation as one of the AD causes is thus greatly reduced. As shown in Figure S11, a significant difference in the viability of N2a cells after 24 h incubation in conditioned media collected separately from the co-incubations of BV-2 cells with oAβ42 and those with mpAβ42 was observed. Owing to the reduced inflammatory responses, the viability of the neuron cells in conditioned medium from the co-incubation of BV-2 cells with the stirring-induced Aβ42 aggregates was thus promoted. These data strongly imply that the magnetic stirring treatment is capable of effectively reducing neuroinflammation, thereby leading to a pronounced increase in the survival of N2a cells. In addition, the preliminary in vivo study showed no obvious tissue damage with the brain receiving the MSB stirring treatment (Figure S12a). The MSBs were mostly degraded over 15 days after the intrahippocampal injection (Figure S12b). No significant increases in cell apoptosis and ROS generation were found from the staining of the brain tissues with caspase 3 marker and with SOSG in the treated mice compared to the control group (Figure S12c). These results further demonstrated the safety and feasibility of this novel approach in practical applications for the AD treatment.

4. Conclusions

In this work, we have demonstrated the successful development of the MSB-stirring based AD therapy system for rapid effective capture of oAβ42 species that are subsequently transformed into large magnetic aggregates (mpAβ42) in vitro. In this manner, the neurotoxicity of oAβ42 against neuronal cells and the oAβ42-induced polarization of microglia to M1 type characterized by high pro-inflammatory propensity can be significantly reduced. Through the increased close contact among oAβ42 species by stirring and magnetic attraction of MSB-entrapped oAβ42 aggregates under rotating magnetic field, rapid effective conversion of neurotoxic oAβ42 species into harmless mpAβ42 can be achieved. The MSB therapy system not only exhibits negligible cytotoxicity toward neuronal cells in the absence or presence of rotating magnetic field, but also greatly reduces the neurotoxicity of oAβ42 by rapid capture of oAβ42 species into mpAβ42 aggregates even with a concentration at 0.3 μM. The magnetic stirring treatment has shown a superior capability of maintaining the functionality of N2a cells in viability, specific protein expression and neurite outgrowth, and reducing the levels of pro-inflammatory cytokines secreted from M1 type microglial cells due to the effective agglutination of toxic oAβ42 species into mpAβ42. With the limited polarization of microglia into M1 type, the effective clearance of mpAβ42 via the phagocytosis of microglia was achieved. The brain tissue histologic study showed no obvious tissue damage with the mice receiving the MSB stirring treatment in the hippocampus area. Neither cell apoptosis nor ROS generation in the brain tissues were found to be significantly increased. The MSBs were extensively degraded over 15 days after the intracranial injection. These results strongly suggest that the magnetic stirring treatment with MSBs be a promising strategy for improving the AD treatment. Further detailed studies concerning the in vivo therapeutic efficacy of the MSB stirring treatment against AD is in progress.

Supplementary Materials

The following are available online at https://www.mdpi.com/2079-4991/10/7/1284/s1. Figure S1: Characterization of SPIONs. (a) TEM image of OA-SPIONs and (b) TEM image of LA/OA-SPIONs. Scale bar: 50 nm. (c) TGA measurement of OA-SPIONs. (d) Field-dependent magnetic curves of OA-SPIONs (black line) and LA/OA-SPIONs (red line) measured at the same Fe concentration. (e) XRD patterns of OA-SPIONs and LA/OA-SPIONs. Figure S2: Alignment of MSBs examined by optical microscopy. (a) The random localization of MSBs in the absence of external magnet. (b) Uniform alignment of MSBs in accordance to the magnet (black arrows). (c) Dispersion of rhodamine B in water droplets by magnetic stirring with MSBs under rotating magnetic field. Figure S3: Colloidal stability over 120 min in different aqueous milieus. Count rates of MSBs in DI water (━), DMEM (━), DMEM containing 10% FBS (━) and PBS (━) at different time intervals with various magnetic stirring speeds: (a) 0, (b) 500, (c) 1500 and (d) 2500 rpm. Error bars represent mean ± s.d. (n = 6). Figure S4: Pronounced effect of capturing oAβ42 by magnetic stirring (2500 rpm) with MSBs (144 μg/mL) into aggregates was observed by LSCM (n = 10). The oAβ42 was stained with ThT and CR. Scale bar: 100 μm. Figure S5: Detailed structural characterizations of npAβ42. (a) Fluorescence intensity of ThT in aqueous solution of Aβ42 (20 μM) as a function of time. (b) CR absorption spectra (420–580 nm) of Aβ42 (20 μM) with different incubation time intervals. (c) TEM and HR-TEM images of oAβ42. (d) TEM and HR-TEM images of npAβ42. Figure S6: Capture of npAβ42 into large aggregates by MSB stirring (n = 10). (a) Fluorescence images of npAβ42 treated with magnetic stirring as a function of the concentration of MSBs at 2500 rpm for 20 min. The Aβ42 concentration was 20 μM. The npAβ42 was attained from incubation of oAβ42 in PBS under mild shaking at 37 °C for 7 days. Scale bar: 100 μm. (b) Total signal areas of large aggregates by ThT and CR staining. *** p < 0.005, ** p < 0.01, * p < 0.05 and N.S. p > 0.05. Error bars represent mean ± s.d. (n = 10). Figure S7: (a) LSCM images of the neuron (N2a) outgrowth with magnetic stirring of various speeds for 2 h (MSB 144 μg mL−1). Cytoskeleton was stained with F-actin marker. Scale bar: 100 μm. The viability of N2a cells receiving the magnetic stirring treatment with MSBs (144 μg mL−1) at various stirring speeds. (b) Cell viability of N2a cells after the capture of oAβ42 by magnetic stirring with MSBs of different concentrations at 2500 rpm for preset time intervals. The cell viability was evaluated by MTT assay. Error bars represent mean ± s.d. (n = 6). Figure S8: Representative LSCM images of N2a cells before and after the magnetic stirring treatment. LSCM images of N2a cells treated with either oAβ42 only or oAβ42/MSBs (oAβ42 concentration: 160 μM; MSB 144 μg mL−1) with and without magnetic stirring (2500 rpm) for 2 h (n = 6). The cell nuclei and cytoskeleton were stained with Hoechst 33342 and F-actin marker, respectively. Scale bar: 50 μm. Quantitative data of neurite length (μm) and number with and without magnetic stirring treatment are also included. *** p < 0.005. Error bars represent mean ± s.d. (n = 6). Figure S9: Neuron-specific protein expression of N2a cells treated either with npAβ42 or mpAβ42 (n = 3). (a) Effects of npAβ42 and mpAβ42 on neuron-specific protein expression (MAP2a/MAP2b, MAP2c, NF-M and NeuN). β-actin was used as the loading control. (b) Relative signal intensities of individual neuron-specific proteins from N2a cells after the npAβ42 or mpAβ42 treatment. The Aβ42 concentration was 160 μM. * p < 0.05. Error bars represent mean ± s.d. (n = 3). Figure S10: Phagocytic actions of BV-2 cells toward oAβ42, npAβ42 and mpAβ42. Representative LSCM images of the Aβ42 uptake by BV-2 cells (n = 8). Aβ42 in different forms was IHC-stained using 6E10 as the primary antibody (λex = 565 nm, λem = 680–730 nm). Cell nuclei and cytoskeleton were stained with Hoechst 33342 and F-actin marker, respectively. Scale bar: 50 μm. Figure S11: Cell viability of N2a cells after 24 h-incubation in conditioned media collected separately from the co-incubations of BV-2 cells with oAβ42 and BV-2 cells with mpAβ42. *** p < 0.005, ** p < 0.01. Error bars represent mean ± s.d. (n = 6). Figure S12: Brain tissue examination with (a) H&E (b) prussian blue (MSBs) and (c) DAPI (nuclei), SOSG (ROS) and caspase-3 (cell apoptosis) IHC staining from healthy C57BL/6J mice receiving MSB stirring treatment (2400 rpm, 20 min) (n = 3). Scale bars for (a) and (b): 500 μm. Scale bar for (c): 100 μm. Table S1: Characterization of OA-SPIONs and LA/OA-SPIONs by DLS. Video S1: Magnetic sitrring of MSBs recorded by charged-coupled device (CCD) video camera. Vidoe S2: The blinking phenomenon caused by light scattering with MSB stirring recorded by charged-coupled device (CCD) video camera.

Author Contributions

Y.-C.T., J.-C.L., T.-I.L., and H.-C.C. conceived and designed the experiments. C.-Y.C. provided the materials and coordinated the western blotting study. J.-C.L. prepared the materials and carried out the experiments. Y.-C.T., C.-S.C., and H.-C.C. co-wrote the manuscript. M.-Y.S. and I.-L.L. participated data analyses and discussion. All authors discussed the results and commented on the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This work is supported by the Ministry of Science and Technology, Taiwan (MOST 108-2314-B-007-004-MY3 and MOST 107-2221-E-007-032-MY3); the National Tsing Hua University (109Q2520E1); Hsinchu Mackay Memorial Hospital, Taiwan (MMHTH-TH-10905); and China Medical University Hsinchu Hospital (CMUHCH-DMR-109-006), Taiwan.

Conflicts of Interest

The authors declare no competing interests.

References

  1. Klein, W.L.; Krafft, G.A.; Finch, C.E. Targeting small Abeta oligomers: The solution to an Alzheimer’s disease conundrum? Trends Neurosci. 2001, 24, 219–224. [Google Scholar] [CrossRef]
  2. Maia, M.A.; Sousa, E. BACE-1 and γ-secretase as therapeutic targets for Alzheimer’s disease. Pharmaceuticals 2019, 12, 41. [Google Scholar] [CrossRef] [PubMed]
  3. Cummings, J.; Lee, G.; Ritter, A.; Sabbagh, M.; Zhong, K. Alzheimer’s disease drug development pipeline: 2019. Alzheimers Dement. 2019, 5, 272–293. [Google Scholar] [CrossRef]
  4. Panza, F.; Lozupone, M.; Logroscino, G.; Imbimbo, B.P. A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease. Nat. Rev. Neurol. 2019, 15, 73–88. [Google Scholar] [CrossRef] [PubMed]
  5. Doody, R.S.; Thomas, R.G.; Farlow, M.; Iwatsubo, T.; Vellas, B.; Joffe, S.; Kieburtz, K.; Raman, R.; Sun, X.; Aisen, P.S. Phase 3 trials of Solanezumab for mild-to-moderate Alzheimer’s disease. N. Engl. J. Med. 2014, 370, 311–321. [Google Scholar] [CrossRef] [PubMed]
  6. Lauren, J.; Gimbel, D.A.; Nygaard, H.B.; Gilbert, J.W.; Strittmatter, S.M. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009, 457, 1128–1132. [Google Scholar] [CrossRef] [PubMed]
  7. Zhang, Y.; Zhao, Y.; Zhang, L.; Yu, W.; Wang, Y.; Chang, W. Cellular prion protein as a receptor of toxic amyloid-β42 oligomers is important for Alzheimer’s disease. Front. Cell Neurosci. 2019, 13, 339. [Google Scholar] [CrossRef]
  8. EI-Shimy, I.A.; Heikal, O.A.; Hamdi, N. Minocycline attenuates Aβ oligomers-induced pro-inflammatory phenotype in primary microglia while enhancing Aβ fibrils phagocytosis. Neurosci. Lett. 2015, 609, 36–41. [Google Scholar] [CrossRef]
  9. Cherry, J.D.; Olschowka, J.A.; O’Banion, M.K. Neuroinflammation and M2 microglia: The good, the bad, and the inflamed. J. Neuroinflamm. 2014, 11, 98. [Google Scholar] [CrossRef]
  10. Block, M.L.; Hong, J.S. Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism. Prog. Neurobiol. 2005, 76, 77–98. [Google Scholar] [CrossRef]
  11. Tobinick, E.L.; Gross, H. Rapid cognitive improvement in Alzheimer’s disease following perispinal etanercept administration. J. Neuroinflamm. 2008, 5, 2. [Google Scholar] [CrossRef] [PubMed]
  12. De Felice, F.G.; Ferreira, S.T. Inflammation, defective insulin signalling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes 2014, 63, 2262–2272. [Google Scholar] [CrossRef] [PubMed]
  13. Lee, C.Y.; Landreth, G.E. The role of microglia in amyloid clearance from the AD brain. J. Neural Transm. 2010, 117, 949–960. [Google Scholar] [CrossRef]
  14. Yang, W.; Wu, Q.; Yuan, C.; Gao, J.; Xiao, M.; Gu, M.; Ding, J.; Hu, G. Aquaporin-4 mediates astrocyte response to β-amyloid. Cell Neruosci. 2012, 49, 406–414. [Google Scholar] [CrossRef] [PubMed]
  15. Kanekiyo, T.; Cirrito, J.R.; Liu, C.C.; Shinohara, M.; Li, J.; Schuler, D.R.; Shinohara, M.; Holtzman, D.M.; Bu, G. Neuronal clearance of amyloid-β by endocytic receptor LRP1. J. Neurosci. 2013, 33, 19276–19283. [Google Scholar] [CrossRef]
  16. Tang, Y.; Le, W. Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol. Neurobiol. 2016, 53, 1181–1194. [Google Scholar] [CrossRef]
  17. Winkler, E.; Julius, A.; Steiner, H.; Langosch, D. Homodimerization protects the amyloid precursor protein C99 fragment from cleavage by γ-secretase. Biochemistry 2015, 54, 6149–6152. [Google Scholar] [CrossRef]
  18. Parajuli, B.; Sonobe, Y.; Horiuchi, H.; Takeuchi, H.; Mizuno, T.; Suzumura, A. Oligomeric amyloid β induces IL-1β processing via production of ROS: Implicationin Alzheimer’s disease. Cell Death Dis. 2013, 4, e975. [Google Scholar] [CrossRef]
  19. Prade, E.; Barucker, C.; Sarkar, R.; Althoff-Ospelt, G.; Lopez del Amo, J.M.; Hossain, S.; Zhong, Y.; Multhaup, G.; Reif, B. Sulindac sulfide induces the formation of large oligomeric aggregates of the Alzheimer’s disease amyloid-β peptide which exhibit reduced neurotoxicity. Biochemistry 2016, 55, 1839–1849. [Google Scholar] [CrossRef]
  20. Bieschke, J.; Herbst, M.; Wiglenda, T.; Friedrich, R.P.; Boeddrich, A.; Schiele, F.; Kleckers, D.; Lopez del Amo, J.M.; Gruning, B.A.; Wang, Q.; et al. Small-molecule conversion of toxic oligomers to nontoxic β-sheet-rich amyloid fibrils. Nat. Chem. Biol. 2011, 8, 93–101. [Google Scholar] [CrossRef]
  21. Keskin, A.D.; Kekus, M.; Adelsberger, H.; Neumann, U.; Shimshek, D.R.; Song, B.; Zott, B.; Peng, T.; Forstl, H.; Staufenbiel, M.; et al. BACE inhibition-dependent repair of Alzheimer’s pathophysiology. Proc. Natl. Acad. Sci. USA 2017, 114, 8631–8636. [Google Scholar] [CrossRef] [PubMed]
  22. Meier, S.R.; Syvanen, S.; Hultgvist, G.; Fang, X.T.; Roshanbin, S.; Lannfelt, L.; Neumann, U.; Sehlin, D. Antibody-based in vivo PET imaging detects amyloid-β reduction in Alzheimer transgenic mice after BACE-1 inhibition. J. Nucl. Med. 2018, 59, 1885–1891. [Google Scholar] [CrossRef] [PubMed]
  23. Huang, W.C.; Lu, I.L.; Chiang, W.H.; Lin, Y.W.; Tsai, Y.C.; Chen, H.H.; Chang, C.W.; Chiang, C.S.; Chiu, H.C. Tumortropic adipose-derived stem cells carrying smart nanotherapeutics for targeted delivery and dual-modality therapy of orthotopic glioblastoma. J. Control Release 2017, 254, 119–130. [Google Scholar] [CrossRef]
  24. Hu, Y.; He, L.; Yin, Y. Magnetically responsive photonic nanochains. Angew. Chem. Int. Ed. Engl. 2011, 50, 3747–3750. [Google Scholar] [CrossRef]
  25. Dahlgren, K.N.; Manelli, A.M.; Stine, W.B., Jr.; Baker, L.K.; Krafft, G.A.; LaDu, M.J. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J. Biol. Chem. 2002, 277, 32046–32053. [Google Scholar] [CrossRef] [PubMed]
  26. Lambert, M.P.; Viola, K.L.; Chromy, B.A.; Chang, L.; Morgan, T.E.; Yu, J.; Venton, D.L.; Krafft, G.A.; Finch, C.E.; Klein, W.L. Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J. Neurochem. 2001, 79, 595–605. [Google Scholar] [CrossRef]
  27. Kuznetsova, I.M.; Sulatskaya, A.I.; Uversky, V.N.; Turoverov, K.K. Analyzing thioflavin T binding to amyloid fibrils by an equilibrium microdialysis-based technique. PLoS ONE 2012, 7, e30724. [Google Scholar] [CrossRef]
  28. Hudson, S.A.; Ecroyd, H.; Kee, T.W.; Carver, J.A. The thioflavin T fluorescence assay for amyloid fibril detection can be biased by the presence of exogenous compounds. FEBS J. 2009, 276, 5960–5972. [Google Scholar] [CrossRef]
  29. Huang, C.; Xu, D.; Zhang, K.; Shentu, J.; Yan, S.; Wu, D.; Wang, Q.; Cui, W. A11-positive β-amyloid oligomer preparation and assessment using dot blotting analysis. J. Vis. Exp. 2018, 135, 57592. [Google Scholar]
  30. Xue, C.; Tran, J.; Wang, H.; Park, G.; Hsu, F.; Guo, Z. Aβ42 fibril formation from predominantly oligomeric samples suggests a link between oligomer heterogeneity and fibril polymorphism. R. Soc. Open Sci. 2019, 6, 190179. [Google Scholar] [CrossRef]
  31. Chowdhury, S.R.; Mondal, S.; Muthuraj, B.; Balaji, S.N.; Trivedi, V.; Iyer, P.K. Remarkably efficient blood-brain barrier crossing polyfluorene-chitosan nanoparticle selectively tweaks amyloid oligomer in cerebrospinal fluid and Aβ1–40. ACS Omega 2018, 3, 8059–8066. [Google Scholar] [CrossRef] [PubMed]
  32. Sun, L.; Zhong, Y.; Gui, J.; Wang, X.; Zhuang, X.; Weng, J. A hydrogel biosensor for high selective and sensitive detection of amyloid-beta oligomers. Int. J. Nanomed. 2018, 13, 843–856. [Google Scholar] [CrossRef] [PubMed]
  33. Fischer, D.; Li, Y.; Ahlemeyer, B.; Krieglstein, J.; Kissel, T. In vitro cytotoxicity testing of polycations: Influence of polymer structure on cell viability and hemolysis. Biomaterials 2003, 24, 1121–1131. [Google Scholar] [CrossRef]
  34. Wang, W.; Hou, T.T.; Jia, L.F.; Wu, Q.Q.; Quan, M.N.; Jia, J.P. Toxic amyloid-β oligomers induced self-replication in astrocytes triggering neuronal injury. EBioMedicine 2019, 42, 174–187. [Google Scholar] [CrossRef] [PubMed]
  35. Chakrabarty, P.; Tianbai, L.; Herring, A.; Ceballos-Diaz, C.; Das, P.; Golde, T.E. Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition. Mol. Neurodegener. 2012, 7, 36. [Google Scholar] [CrossRef] [PubMed]
  36. Jean, Y.Y.; Baleriola, J.; Fa, M.; Hengst, U.; Troy, C.M. Stereotaxic infusion of oligomeric amyloid-beta into the mouse hippocampus. J. Vis. Exp. 2015, 100, e52805. [Google Scholar] [CrossRef]
  37. Chong, W.H.; Chin, L.K.; Tan, R.L.; Wang, H.; Liu, A.Q.; Chen, H. Stirring in suspension: Nanometer-sized magnetic stir bars. Angew. Chem. Int. Ed. Engl. 2013, 33, 8570–8573. [Google Scholar] [CrossRef]
  38. Malvindi, M.A.; De Matteis, V.; Galeone, A.; Brunetti, V.; Anyfantis, G.C.; Athanassiou, A.; Cingolani, R.; Pompa, P.P. Toxicity assessment of silica coated iron oxide nanoparticles and biocompatibility improvement by surface engineering. PLoS ONE 2014, 9, e85835. [Google Scholar] [CrossRef]
  39. Younan, N.D.; Viles, J.H. A comparison of three fluorophores for the detection of amyloid fibers and prefibrillar oligomeric assemblies. ThT (Thioflavin T); ANS (1-Anilinonaphthalene-8-sulfonic Acid); and bisANS (4,4’-Dianilino-1,1’-binaphthyl-5,5’-disulfonic Acid). Biochemistry 2015, 54, 4297–4306. [Google Scholar] [CrossRef]
  40. Biancalana, M.; Koide, S. Molecular mechanism of Thioflavin-T binding to amyloid fibrils. Biochim. Biophys. Acta 2010, 1804, 1405–1412. [Google Scholar] [CrossRef]
  41. Stsiapura, V.I.; Maskevich, A.A.; Kuzmitsky, V.A.; Turoverov, K.K.; Kuznetsova, I.M. Computational study of thioflavin T torsional relaxation in the excited state. J. Phys. Chem. A 2007, 111, 4829–4835. [Google Scholar] [CrossRef] [PubMed]
  42. Xue, C.; Lin, T.Y.; Chang, D.; Guo, Z. Thioflavin T as an amyloid dye: Fibril quantification, optimal concentration and effect on aggregation. R. Soc. Open Sci. 2017, 4, 160696. [Google Scholar] [CrossRef] [PubMed]
  43. Frid, P.; Anisimov, S.V.; Popovic, N. Congo red and protein aggregation in neurodegenerative diseases. Brain Res. Rev. 2007, 53, 135–160. [Google Scholar] [CrossRef] [PubMed]
  44. Meehan, S.; Berry, Y.; Luisi, B.; Dobson, C.M.; Carver, J.A.; MacPhee, C.E. Amyloid fibril formation by lens crystallin proteins and its implications for cataract formation. J. Biol. Chem. 2004, 279, 3413–3419. [Google Scholar] [CrossRef] [PubMed]
  45. Sengupta, U.; Nilson, A.N.; Kayed, R. The Role of amyloid-β oligomers in toxicity, propagation, and immunotherapy. EBioMedicine 2016, 6, 42–49. [Google Scholar] [CrossRef]
  46. Kayed, R.; Lasagna-Reeves, C.A. Molecular mechanisms of amyloid oligomers toxicity. J. Alzheimers Dis. 2013, 33, 67–78. [Google Scholar] [CrossRef]
  47. Kumar, S.; Wirths, O.; Stuber, K.; Wunderlich, P.; Koch, P.; Theil, S.; Rezaei-Ghaleh, N.; Zweckstetter, M.; Bayer, T.A.; Brustle, O.; et al. Walter, Phosphorylation of the amyloid β-peptide at Ser26 stabilizes oligomeric assembly and increases neurotoxicity. Acta Neuropathol. 2016, 131, 525–537. [Google Scholar] [CrossRef]
  48. Benilova, I.; Karran, E.; De Strooper, B. The toxic Aβ oligomer and Alzheimer’s disease: An emperor in need of clothes. Nat. Neurosci. 2012, 15, 349–357. [Google Scholar] [CrossRef]
  49. Doi, Y.; Mizuno, T.; Maki, Y.; Jin, S.; Mizoguchi, H.; Ikeyama, M.; Doi, M.; Michikawa, M.; Takeuchi, H.; Suzumura, A. Microglia activated with the toll-like receptor 9 ligand CpG attenuate oligomeric amyloid {beta} neurotoxicity in in vitro and in vivo models of Alzheimer’s disease. Am. J. Pathol. 2009, 5, 2121–2132. [Google Scholar] [CrossRef]
  50. Suzumura, A. Neurotoxicity by microglia: The mechanisms and potential therapeutic strategy. Fukuoka Igaku Zasshi 2009, 1, 243–247. [Google Scholar]
  51. Richard, K.L.; Filali, M.; Prefontaine, P.; Rivest, S. Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1–42 and delay the cognitive decline in a mouse model of Alzheimer’s disease. J. Neurosci. 2008, 28, 5784–5793. [Google Scholar] [CrossRef] [PubMed]
  52. Tahara, K.; Kim, H.D.; Jin, J.J.; Maxwell, J.A.; Li, L.; Fukuchi, K. Role of toll-like receptor signalling in Abeta uptake and clearance. Brain 2006, 129, 3006–3019. [Google Scholar] [CrossRef] [PubMed]
  53. Fujikura, M.; Iwahara, N.; Hisahara, S.; Kawamata, J.; Matsumura, A.; Yokokawa, K.; Saito, T.; Manabe, T.; Matsushita, T.; Suzuki, S.; et al. CD14 and toll-like receptor 4 promote fibrillar Aβ42 uptake by microglia through a clathrin-mediated pathway. J. Alzheimers Dis. 2019, 68, 323–337. [Google Scholar] [CrossRef] [PubMed]
  54. Geloso, M.C.; Corvino, V.; Marchese, E.; Serrano, A.; Michetti, F.; D’Ambrosi, N. The dual role of microglia in ALS: Mechanisms and therapeutic approaches. Front. Aging Neurosci. 2017, 9, 242. [Google Scholar] [CrossRef]
Nanomaterials 10 01284 g001
Figure 1. Illustration of the effective therapeutic action by capture of oAβ42 species into magnetic plaques and enhanced cellular clearance by the M2 type microglial cells for AD treatment.
Figure 1. Illustration of the effective therapeutic action by capture of oAβ42 species into magnetic plaques and enhanced cellular clearance by the M2 type microglial cells for AD treatment.
Nanomaterials 10 01284 g001
Nanomaterials 10 01284 g002
Figure 2. Characterization of microscale silica-coated iron oxide stir bars (MSBs). Morphology of MSBs examined by (a) optical microscope in aqueous solution and (b) SEM in dry state. (c) TEM image of MSBs. Scale bar: 2 μm. (d) HR-TEM image of MSBs. Scale bar: 100 nm.
Figure 2. Characterization of microscale silica-coated iron oxide stir bars (MSBs). Morphology of MSBs examined by (a) optical microscope in aqueous solution and (b) SEM in dry state. (c) TEM image of MSBs. Scale bar: 2 μm. (d) HR-TEM image of MSBs. Scale bar: 100 nm.
Nanomaterials 10 01284 g002
Nanomaterials 10 01284 g003
Figure 3. Capture of oAβ42 into mpAβ42 by magnetic stirring with MSBs. (a) Fluorescence images of oAβ42 (20 μM) treated with magnetic stirring as a function of the concentration of MSBs at 2500 rpm for 20 min (n = 10). Scale bar: 100 μm. (b) The total and mean signal areas detected from the Aβ42 aggregation induced by magnetic stirring with MSBs were included. *** p < 0.005 and N.S. p > 0.05. Error bars represent mean ± s.d. (n = 10).
Figure 3. Capture of oAβ42 into mpAβ42 by magnetic stirring with MSBs. (a) Fluorescence images of oAβ42 (20 μM) treated with magnetic stirring as a function of the concentration of MSBs at 2500 rpm for 20 min (n = 10). Scale bar: 100 μm. (b) The total and mean signal areas detected from the Aβ42 aggregation induced by magnetic stirring with MSBs were included. *** p < 0.005 and N.S. p > 0.05. Error bars represent mean ± s.d. (n = 10).
Nanomaterials 10 01284 g003
Nanomaterials 10 01284 g004
Figure 4. Structural analyses of oAβ42 and mpAβ42 by TEM and AFM. (a) TEM images of effective capture of oAβ42 into mpAβ42 via magnetic stirring. Scale bar: 2 μm. (b) Examination of mpAβ42 by AFM. 2D topographic images of oAβ42, oAβ42 + MSBs (0 rpm), and oAβ42 + MSBs (2500 rpm); and 3D topographic representations of oAβ42, oAβ42 + MSBs (0 rpm), and oAβ42 + MSBs (2500 rpm).
Figure 4. Structural analyses of oAβ42 and mpAβ42 by TEM and AFM. (a) TEM images of effective capture of oAβ42 into mpAβ42 via magnetic stirring. Scale bar: 2 μm. (b) Examination of mpAβ42 by AFM. 2D topographic images of oAβ42, oAβ42 + MSBs (0 rpm), and oAβ42 + MSBs (2500 rpm); and 3D topographic representations of oAβ42, oAβ42 + MSBs (0 rpm), and oAβ42 + MSBs (2500 rpm).
Nanomaterials 10 01284 g004
Nanomaterials 10 01284 g005
Figure 5. Effective therapeutic action by capture of oAβ42 under magnetic stirring with MSBs. (a) In vitro cytotoxicity of N2a cells with or without magnetic stirring treatment by MTT and (b) trypan blue assays. The experiment was independently repeated three times. Error bars show standard deviations. (c) LDH release from N2a cells with and without the oAβ42 capture by the MSB stirring treatment. (d) Effects of oAβ42 on neuron-specific protein expression (MAP2 and NF-M) with and without the magnetic stirring treatment (n = 6). Cell nuclei were stained with Hoechst 33342 (λex = 405 nm, λem = 450–500 nm), microtubules with MAP2 marker (λex = 495 nm, λem = 500–550 nm) and neurofilaments with NF-M marker (λex = 633 nm, λem = 640–660 nm). Scale bar: 50 μm. *** p < 0.005 and N.S. p > 0.05. Error bars represent mean ± s.d. (n = 8).
Figure 5. Effective therapeutic action by capture of oAβ42 under magnetic stirring with MSBs. (a) In vitro cytotoxicity of N2a cells with or without magnetic stirring treatment by MTT and (b) trypan blue assays. The experiment was independently repeated three times. Error bars show standard deviations. (c) LDH release from N2a cells with and without the oAβ42 capture by the MSB stirring treatment. (d) Effects of oAβ42 on neuron-specific protein expression (MAP2 and NF-M) with and without the magnetic stirring treatment (n = 6). Cell nuclei were stained with Hoechst 33342 (λex = 405 nm, λem = 450–500 nm), microtubules with MAP2 marker (λex = 495 nm, λem = 500–550 nm) and neurofilaments with NF-M marker (λex = 633 nm, λem = 640–660 nm). Scale bar: 50 μm. *** p < 0.005 and N.S. p > 0.05. Error bars represent mean ± s.d. (n = 8).
Nanomaterials 10 01284 g005
Nanomaterials 10 01284 g006
Figure 6. Neuron-specific protein expression of N2a cells receiving the magnetic stirring treatment. (a) Effects of oAβ42 on protein expression (MAP2a/MAP2b, MAP2c, NF-M, and NeuN) with and without the magnetic stirring (n = 3). β-actin was used as the loading control. The oAβ42 concentration was 160 μM. (b) The relative intensities of neuron-specific protein expression of N2a cells receiving magnetic stirring with MSBs were included.
Figure 6. Neuron-specific protein expression of N2a cells receiving the magnetic stirring treatment. (a) Effects of oAβ42 on protein expression (MAP2a/MAP2b, MAP2c, NF-M, and NeuN) with and without the magnetic stirring (n = 3). β-actin was used as the loading control. The oAβ42 concentration was 160 μM. (b) The relative intensities of neuron-specific protein expression of N2a cells receiving magnetic stirring with MSBs were included.
Nanomaterials 10 01284 g006
Nanomaterials 10 01284 g007
Figure 7. Phagocytic action of BV-2 cells. (a) Laser scanning confocal microscope (LSCM) images of BV-2 cells after co-incubation with oAβ42, npAβ42, and mpAβ42, respectively (n = 8). Aβ42 in different forms was IHC stained using 6E10 as the primary antibody (λex = 565 nm, λem = 680–730 nm). Scale bar: 50 μm. (b) Relative uptake index of Aβ42 by BV-2 cells. One-way ANOVA was used to examine the mean differences between the end points of the data groups. ** p < 0.01. Error bars represent mean ± s.d. (n = 8).
Figure 7. Phagocytic action of BV-2 cells. (a) Laser scanning confocal microscope (LSCM) images of BV-2 cells after co-incubation with oAβ42, npAβ42, and mpAβ42, respectively (n = 8). Aβ42 in different forms was IHC stained using 6E10 as the primary antibody (λex = 565 nm, λem = 680–730 nm). Scale bar: 50 μm. (b) Relative uptake index of Aβ42 by BV-2 cells. One-way ANOVA was used to examine the mean differences between the end points of the data groups. ** p < 0.01. Error bars represent mean ± s.d. (n = 8).
Nanomaterials 10 01284 g007
Nanomaterials 10 01284 g008
Figure 8. Cytokine secretion from BV-2 cells treated with oAβ42, mpAβ42, and npAβ42, respectively, for 6 h. Concentrations of IL-1β (a), TNF-α (b), and IL-10 (c) were determined in triplicate wells by ELISA analyses. The experiments were independently repeated three times and one-way ANOVA was used to examine the mean differences between the data groups. *** p < 0.005, ** p < 0.01, * p < 0.05, and N.S. p > 0.05. Error bars represent mean ± s.d. (n = 3).
Figure 8. Cytokine secretion from BV-2 cells treated with oAβ42, mpAβ42, and npAβ42, respectively, for 6 h. Concentrations of IL-1β (a), TNF-α (b), and IL-10 (c) were determined in triplicate wells by ELISA analyses. The experiments were independently repeated three times and one-way ANOVA was used to examine the mean differences between the data groups. *** p < 0.005, ** p < 0.01, * p < 0.05, and N.S. p > 0.05. Error bars represent mean ± s.d. (n = 3).
Nanomaterials 10 01284 g008

Share and Cite

MDPI and ACS Style

Tsai, Y.-C.; Luo, J.-C.; Liu, T.-I.; Lu, I.-L.; Shen, M.-Y.; Chuang, C.-Y.; Chern, C.-S.; Chiu, H.-C. Capturing Amyloid-β Oligomers by Stirring with Microscaled Iron Oxide Stir Bars into Magnetic Plaques to Reduce Cytotoxicity toward Neuronal Cells. Nanomaterials 2020, 10, 1284. https://doi.org/10.3390/nano10071284

AMA Style

Tsai Y-C, Luo J-C, Liu T-I, Lu I-L, Shen M-Y, Chuang C-Y, Chern C-S, Chiu H-C. Capturing Amyloid-β Oligomers by Stirring with Microscaled Iron Oxide Stir Bars into Magnetic Plaques to Reduce Cytotoxicity toward Neuronal Cells. Nanomaterials. 2020; 10(7):1284. https://doi.org/10.3390/nano10071284

Chicago/Turabian Style

Tsai, Yuan-Chung, Jing-Chian Luo, Te-I Liu, I-Lin Lu, Ming-Yin Shen, Chun-Yu Chuang, Chorng-Shyan Chern, and Hsin-Cheng Chiu. 2020. "Capturing Amyloid-β Oligomers by Stirring with Microscaled Iron Oxide Stir Bars into Magnetic Plaques to Reduce Cytotoxicity toward Neuronal Cells" Nanomaterials 10, no. 7: 1284. https://doi.org/10.3390/nano10071284

APA Style

Tsai, Y.-C., Luo, J.-C., Liu, T.-I., Lu, I.-L., Shen, M.-Y., Chuang, C.-Y., Chern, C.-S., & Chiu, H.-C. (2020). Capturing Amyloid-β Oligomers by Stirring with Microscaled Iron Oxide Stir Bars into Magnetic Plaques to Reduce Cytotoxicity toward Neuronal Cells. Nanomaterials, 10(7), 1284. https://doi.org/10.3390/nano10071284

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop